Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.

Autor: Ackerson BK; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Bruxvoort KJ; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA., Qian L; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Sy LS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Qiu S; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Tubert JE; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Lee GS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Ku JH; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Florea A; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Luo Y; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Bathala R; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Stern J; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Choi SK; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Takhar HS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Aragones M; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Marks MA; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA., Anderson EJ; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA., Zhou CK; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA., Sun T; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA., Talarico CA; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA.; Epidemiology, AstraZeneca, Gaithersburg, MD, USA., Tseng HF; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Jazyk: angličtina
Zdroj: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2335052. Date of Electronic Publication: 2024 Apr 04.
DOI: 10.1080/21645515.2024.2335052
Abstrakt: Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against circulating sublineages is important to inform the potential need for vaccination with updated vaccines. In this test-negative study at Kaiser Permanente Southern California, sequencing-confirmed BA.4/BA.5- or XBB-related SARS-CoV-2-positive cases (September 1, 2022 to June 30, 2023), were matched 1:3 to SARS-CoV-2-negative controls. We assessed mRNA-1273 bivalent relative (rVE) and absolute vaccine effectiveness (VE) compared to ≥2 or 0 doses of original monovalent vaccine, respectively. The rVE analysis included 20,966 cases and 62,898 controls. rVE (95%CI) against BA.4/BA.5 at 14-60 days and 121-180 days was 52.7% (46.9-57.8%) and 35.5% (-2.8-59.5%) for infection, and 59.3% (49.7-67.0%) and 33.2% (-28.2-68.0%) for Emergency Department/Urgent Care (ED/UC) encounters. For BA.4/BA.5-related hospitalizations, rVE was 71.3% (44.9-85.1%) and 52.0% (-1.2-77.3%) at 14-60 days and 61-120 days, respectively. rVE against XBB at 14-60 days and 121-180 days was 48.8% (33.4-60.7%) and -3.9% (-18.1-11.3%) for infection, 70.7% (52.4-82.0%) and 15.7% (-6.0-33.2%) for ED/UC encounters, and 87.9% (43.8-97.4%) and 57.1% (17.0-77.8%) for hospitalization. VE and subgroup analyses (age, immunocompromised status, previous SARS-CoV-2 infection) results were similar to rVE analyses. rVE of mRNA-1273 bivalent vaccine against BA.4/BA.5 and XBB infections, ED/UC encounters, and hospitalizations waned over time. Periodic revaccination with vaccines targeting emerging variants may be important in reducing COVID-19 morbidity and mortality.
Databáze: MEDLINE